<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the third most common cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>death</z:hpo> in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>Early identification and treatment of pre-cancerous colorectal lesions, or node-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> are highly effective interventions that substantially reduce disease-specific mortality </plain></SENT>
<SENT sid="2" pm="."><plain>Colonoscopy remains a highly effective primary screening tool based on its excellent diagnostic accuracy, and its ability to remove pre-cancerous lesions </plain></SENT>
<SENT sid="3" pm="."><plain>However, the nature of the procedure limits compliance with colonoscopy intended for population-based <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening </plain></SENT>
<SENT sid="4" pm="."><plain>A significant advance in the screening and care of these patients could be realized by blood-based biomarkers, which could accurately identify patients at-risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development whom might benefit from early and/or more frequent surveillance for disease </plain></SENT>
<SENT sid="5" pm="."><plain>We reviewed and herein discuss the potential for serum based DNA methylation biomarkers for screening and early detection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>